Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the ATTR-CM market in the next 3 years.
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.
Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership changes, and prepares for commercialization.
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
